Ever wondered how a two-drug HIV treatment fares in real life? Let's dive into the facts about Dolutegravir (DTG) and Lamivudine (3TC). Researchers found that people living with HIV who took this combo had high rates of virus suppression and low rates of failure, discontinuation, and drug resistance in clinical trials. But what about outside the lab? Real-world evide...
In today's world, HIV is more of a manageable condition than a death sentence, thanks to improved treatments. But folks living with HIV still face a tougher challenge when it comes to both mental and physical health. They're not only dealing with health issues, but also grappling with economic and social problems. The Positive Voices survey is a big deal in the UK. I...
Pneumocystis jirovecii pneumonia, or PCP, is a severe lung infection that often affects people living with HIV (HIV+) who have weakened immune systems. The go-to treatment for PCP is trimethoprim-sulfamethoxazole (TMP-SMX), even though it comes with some side effects. But is TMP-SMX really the best option? Let's dive into the research to compare different treatments ...
Imagine you're living with HIV and have to take pills every day. Sounds tough, right? Well, there's a newer option: a shot every month or two. But what do people think about this? Researchers asked 30 adults in the US who are currently on HIV treatment. They wanted to know if questions about their feelings and the ease of their treatment made sense. The participants...
Have you ever wondered how different HIV treatments work for older adults? A study took a close look at how well dolutegravir-based regimens stack up against others like raltegravir-, elvitegravir-, bictegravir-, and darunavir-based regimens. This study involved older veterans living with HIV and aimed to shed some light on real-world treatment patterns and outcomes....
In the heart of Tanzania, there's a story unfolding about adolescents living with HIV (ALHIV). These teens face a significant challenge: they're not sticking to their treatment plans. This can lead to poor health outcomes, all because they're struggling to follow their medication routines. Why is this happening? Well, life in rural areas can be tough. These teens mi...
In early 2021, the FDA approved the first long-acting injectable antiretroviral, cabotegravir/rilpivirine (LA-CAB/RPV), for people with HIV who are doing well on their current treatment. A high body mass index (BMI)—30 kg/m² or more—is known to increase the risk of treatment failure, but there's not much data to confirm this because the studies have been small. A rec...